172 related articles for article (PubMed ID: 37942566)
1. Improved efficiency of daratumumab treatment of multiple myeloma adopting the subcutaneous route: A micro-costing analysis in three Italian hematology centers.
Pradelli L; Massaia M; Todisco E; Gherlinzoni F; Furlan A; La Targia M; Grande E; Tripoli IE; Occhipinti F; Comello F; Iannello F; Bellucci S
Cancer Med; 2023 Dec; 12(23):21480-21489. PubMed ID: 37942566
[TBL] [Abstract][Full Text] [Related]
2. Results of a Time and Motion Survey Regarding Subcutaneous versus Intravenous Administration of Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma.
Slavcev M; Spinelli A; Absalon E; Masterson T; Heuck C; Lam A; De Cock E
Clinicoecon Outcomes Res; 2021; 13():465-473. PubMed ID: 34135605
[TBL] [Abstract][Full Text] [Related]
3. 'Fast but not so Furious': Short observation time after subcutaneous Daratumumab administration is both a safe and cost-effective strategy.
Davis JA; Youngberg H; Gaffney K; Duco M; Hashmi H
Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):e680-e684. PubMed ID: 35414476
[TBL] [Abstract][Full Text] [Related]
4. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial.
Mateos MV; Nahi H; Legiec W; Grosicki S; Vorobyev V; Spicka I; Hungria V; Korenkova S; Bahlis N; Flogegard M; Bladé J; Moreau P; Kaiser M; Iida S; Laubach J; Magen H; Cavo M; Hulin C; White D; De Stefano V; Clemens PL; Masterson T; Lantz K; O'Rourke L; Heuck C; Qin X; Parasrampuria DA; Yuan Z; Xu S; Qi M; Usmani SZ
Lancet Haematol; 2020 May; 7(5):e370-e380. PubMed ID: 32213342
[TBL] [Abstract][Full Text] [Related]
5. Intravenous or subcutaneous natalizumab in patients with relapsing-remitting multiple sclerosis: investigation on efficiency and savings-the EASIER study.
Filippi M; Grimaldi L; Conte A; Totaro R; Valente MR; Malucchi S; Granella F; Cordioli C; Brescia Morra V; Zanetta C; Perini D; Santoni L;
J Neurol; 2024 Jan; 271(1):340-354. PubMed ID: 37715789
[TBL] [Abstract][Full Text] [Related]
6. Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma.
Usmani SZ; Nahi H; Legiec W; Grosicki S; Vorobyev V; Spicka I; Hungria V; Korenkova S; Bahlis NJ; Flogegard M; Bladé J; Moreau P; Kaiser M; Iida S; Laubach J; Magen H; Cavo M; Hulin C; White D; De Stefano V; Lantz K; O'Rourke L; Heuck C; Delioukina M; Qin X; Nnane I; Qi M; Mateos MV
Haematologica; 2022 Oct; 107(10):2408-2417. PubMed ID: 35354247
[TBL] [Abstract][Full Text] [Related]
7. Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma.
Sanchez L; Richter J; Cho HJ; Jagannath S; Madduri D; Parekh S; Richard S; Tam L; Verina D; Chari A
Ther Adv Hematol; 2021; 12():2040620720987075. PubMed ID: 33613930
[TBL] [Abstract][Full Text] [Related]
8. Clinical Administration Characteristics of Subcutaneous and Intravenous Administration of Daratumumab in Patients With Multiple Myeloma at Mayo Clinic Infusion Centers.
Soefje SA; Carpenter C; Carlson K; Awasthi S; Lin TS; Kaila S; Tarjan D; Kayal N; Kirkup C; Wagner TE; Gray KS; Kumar S
JCO Oncol Pract; 2023 Apr; 19(4):e542-e549. PubMed ID: 36758192
[TBL] [Abstract][Full Text] [Related]
9. Subcutaneous daratumumab in Asian patients with heavily pretreated multiple myeloma: subgroup analyses of the noninferiority, phase 3 COLUMBA study.
Iida S; Ishikawa T; Min CK; Kim K; Yeh SP; Usmani SZ; Mateos MV; Nahi H; Heuck C; Qin X; Parasrampuria DA; Gries KS; Qi M; Bahlis N; Ito S
Ann Hematol; 2021 Apr; 100(4):1065-1077. PubMed ID: 33599794
[TBL] [Abstract][Full Text] [Related]
10. Subcutaneous delivery of daratumumab in Japanese patients with relapsed/refractory multiple myeloma.
Shibayama H; Matsumoto M; Kosugi H; Shibayama K; Yamazaki H; Iida S
Int J Hematol; 2021 Jan; 113(1):112-121. PubMed ID: 32915384
[TBL] [Abstract][Full Text] [Related]
11. Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II study.
Chari A; Rodriguez-Otero P; McCarthy H; Suzuki K; Hungria V; Sureda Balari A; Perrot A; Hulin C; Magen H; Iida S; Maisnar V; Karlin L; Pour L; Parasrampuria DA; Masterson T; Kosh M; Yang S; Delioukina M; Qi M; Carson R; Touzeau C
Br J Haematol; 2021 Mar; 192(5):869-878. PubMed ID: 33216361
[TBL] [Abstract][Full Text] [Related]
12. Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO).
San-Miguel J; Usmani SZ; Mateos MV; van de Donk NWCJ; Kaufman JL; Moreau P; Oriol A; Plesner T; Benboubker L; Liu K; Hellemans P; Masterson T; Clemens PL; Luo M; Farnsworth A; Nahi H; Chari A
Haematologica; 2021 Jun; 106(6):1725-1732. PubMed ID: 32354874
[TBL] [Abstract][Full Text] [Related]
13. Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma.
Mateos MV; Rigaudeau S; Basu S; Spicka I; Schots R; Wrobel T; Cook G; Beksac M; Gries KS; Kudva A; Tromp B; Van Rampelbergh R; Pei H; Wroblewski S; Carson R; Delioukina M; White D
J Oncol Pharm Pract; 2023 Jul; 29(5):1172-1177. PubMed ID: 36067063
[TBL] [Abstract][Full Text] [Related]
14. Greater treatment satisfaction in patients receiving daratumumab subcutaneous vs. intravenous for relapsed or refractory multiple myeloma: COLUMBA clinical trial results.
Usmani SZ; Mateos MV; Hungria V; Iida S; Bahlis NJ; Nahi H; Magen H; Cavo M; Hulin C; White D; De Stefano V; Fastenau J; Slavcev M; Heuck C; Qin X; Pei H; Masterson T; Lantz K; Gries KS
J Cancer Res Clin Oncol; 2021 Feb; 147(2):619-631. PubMed ID: 32852632
[TBL] [Abstract][Full Text] [Related]
15. Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma.
Usmani SZ; Nahi H; Mateos MV; van de Donk NWCJ; Chari A; Kaufman JL; Moreau P; Oriol A; Plesner T; Benboubker L; Hellemans P; Masterson T; Clemens PL; Luo M; Liu K; San-Miguel J
Blood; 2019 Aug; 134(8):668-677. PubMed ID: 31270103
[TBL] [Abstract][Full Text] [Related]
16. An evaluation of subcutaneous daratumumab for the treatment of multiple myeloma.
Paul B; Atrash S; Bhutani M; Voorhees P; Hamadeh I; Usmani SZ
Expert Rev Hematol; 2020 Aug; 13(8):795-802. PubMed ID: 32659139
[TBL] [Abstract][Full Text] [Related]
17. Safety and blood levels of daratumumab after switching from intravenous to subcutaneous administration in patients with multiple myeloma.
Yamaoka K; Irie K; Hiramoto N; Hirabatake M; Ikesue H; Hashida T; Shimizu T; Ishikawa T; Muroi N
Invest New Drugs; 2023 Oct; 41(5):761-767. PubMed ID: 37721661
[TBL] [Abstract][Full Text] [Related]
18. Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma.
Zhang T; Wang S; Lin T; Xie J; Zhao L; Liang Z; Li Y; Jiang J
Oncotarget; 2017 May; 8(20):34001-34017. PubMed ID: 28454113
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy: A New Approach to Treating Multiple Myeloma with Daratumumab and Elotuzumab.
Afifi S; Michael A; Lesokhin A
Ann Pharmacother; 2016 Jul; 50(7):555-68. PubMed ID: 27083916
[TBL] [Abstract][Full Text] [Related]
20. Economic Evaluation of Adding Daratumumab to a Regimen of Bortezomib + Dexamethasone in Relapsed or Refractory Multiple Myeloma: Based on the Latest Updated Analysis of CASTOR.
Zeng X; Peng L; Peng Y; Tan C; Wan X
Clin Ther; 2020 Feb; 42(2):251-262.e5. PubMed ID: 31973936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
